|
Research Summary
Translational research in hematologic malignancies, laboratory efforts to forward clinical research protocols in leukemia, lymphoma, myeloma and Waldenstrom's macroglobulinemia
Research Activities
Clonality assays, chromosomal analysis and enzyme assays for assesment of therapy-related leukemia risk. In Vitro anti-sense/chemotherapy combinations for downregulating known chromosomal translocations in CML, mantlecell lymphoma, Bcl-2-related lymphoproliferative disorders. Development of tumor-related vectors for potential post-therapy anti-tumor immunotherapy. Therapeutic clinical trials in hematologic malignancies.
Positions & Appointments
| present |
Director, Hematologic Malignancies Program |
Columbia University Medical Center |
New York, NY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selected Publications:
1. Nichols, G., deCastro, K., Wei, L-X, Griffin, M., Lin, N., Oratzi, A., Murty, V., Vahdat, l., Hesdorffer, C. (2002) Therapy-related myelodysplastic syndrome after autologous transplantation for breast cancer Leukemia
16(9):1673-9
2. Nichols, G.L., Stein, C.A. (2003) Modulation of the Activity of Bcl-2 in Waldenstrom's Macroglobulinemia Using Antisense Oligonucleotides Sem Onc
30(2):
| |
